CoChat

Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial

Open access
Tuñón, José, Steg, Philippe Gabriel, Bhatt, Deepak L, Bittner, Vera A, Díaz, Rafael, Goodman, Shaun G, Jukema, J Wouter, Kim, Yong-Un, Li, Qian H, Mueller, Christian, Parkhomenko, Alexander, Pordy, Robert, Sritara, Piyamitr, Szarek, Michael, White, Harvey D, Zeiher, Andreas M, Schwartz, Gregory G, for the ODYSSEY OUTCOMES Investigators · 2020 · European Heart Journal
Cited by 76

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

Aims: Statins reduce cardiovascular risk in patients with acute coronary syndrome (ACS) and normal-to-moderately impaired renal function. It is not known whether proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors provide similar benefit across a range of renal function. We determined whether effects of the PCSK9 inhibitor alirocumab to reduce cardiovascular events and death after ACS are influenced by renal function. Methods and results: ODYSSEY OUTCOMES compared alirocumab with placebo in patients with recent ACS and dyslipidaemia despite intensive statin treatment. Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2 was exclusionary. In 18 918 patients, baseline eGFR was 82.8 ± 17.6 mL/min/1.73 m2, and low-density lipoprotein cholesterol (LDL-C) was 92 ± 31 mg/dL. At 36 months, alirocumab decreased LDL-C by 48.5% vs. placebo but did not affect eGFR (P = 0.65). Overall, alirocumab reduced risk of the primary outcome (coronary heart disease death, non-fatal myocardial infarction, ischaemic stroke, or unstable angina requiring hospitalization) with fewer deaths. There was no interaction between continuous eGFR and treatment on the primary outcome or death (P = 0.14 and 0.59, respectively). Alirocumab reduced primary outcomes in patients with eGFR ≥90 mL/min/1.73 m2 (n = 7470; hazard ratio 0.784, 95% confidence interval 0.670–0.919; P = 0.003) and 60 to <90 (n = 9326; 0.833, 0.731–0.949; P = 0.006), but not in those with eGFR < 60 (n = 2122; 0.974, 0.805–1.178; P = 0.784). Adverse events other than local injection-site reactions were similar in both groups across all categories of eGFR. Conclusions: In patients with recent ACS, alirocumab was associated with fewer cardiovascular events and deaths across the range of renal function studied, with larger relative risk reductions in those with eGFR > 60 mL/min/1.73 m2.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehaa498

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 76

Metadata

Authors
Tuñón, J., Steg, P. G., Bhatt, D. L., Bittner, V. A., Díaz, R., Goodman, S. G., Jukema, J. W., Kim, Y.-U., Li, Q. H., Mueller, C., Parkhomenko, A., Pordy, R., Sritara, P., Szarek, M., White, H. D., Zeiher, A. M., Schwartz, G. G., & for the ODYSSEY OUTCOMES Investigators
Venue
European Heart Journal
Published
2020-08-21
Volume
41
Issue
42
Pages
4114-4123
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W3080356411
Cited by
76
References
19
FWCI
7.60
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial. https://app.cochat.ai/papers/10.1093/eurheartj/ehaa498
The paper
Tuñón, J., Steg, P. G., Bhatt, D. L., Bittner, V. A., Díaz, R., Goodman, S. G., Jukema, J. W., Kim, Y.-U., Li, Q. H., Mueller, C., Parkhomenko, A., Pordy, R., Sritara, P., Szarek, M., White, H. D., Zeiher, A. M., Schwartz, G. G., & for the ODYSSEY OUTCOMES Investigators. (2020). Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial. European Heart Journal. https://doi.org/10.1093/eurheartj/ehaa498

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.